Literature DB >> 11172360

Clinical studies with silymarin: fibrosis progression is the end point.

D Schuppan, E G Hahn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11172360     DOI： 10.1002/hep.510330230

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

1.  Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats.

Authors:  Mehmet Kanter; Omer Coskun; Mustafa Budancamanak
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

2.  Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study.

Authors:  Paul Angulo; Roberta A Jorgensen; Kris V Kowdley; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

3.  Evaluation of antioxidant activity of Manihot esculenta Crantz in wistar rats.

Authors:  Satish Eknath Bahekar; Ranjana Sushil Kale
Journal:  J Pharm Bioallied Sci       Date:  2016 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.